; on behalf of the French Intergroup for Chronic Myeloid Leukemias BACKGROUND: Several studies have demonstrated that approximately one-half of patients with chronic myeloid leukemia (CML) who receive treatment with tyrosine kinase inhibitors (TKIs) and achieve and maintain a deep molecular response (DMR) are able to successfully discontinue therapy. In patients who have a molecular relapse, a DMR is rapidly regained upon treatment re-initiation. METHODS: The authors report the results from RE-STIM, a French observational, multicenter study that evaluated treatment-free remission (TFR) in 70 patients who re-attempted TKI discontinuation after a first unsuccessful attempt. After the second TKI discontinuation attempt, the trigger for treatment re-introduction was the loss of a major molecular response in all patients. RESULTS: The median follow-up was 38.3 months (range, 4.7-117 months), and 45 patients (64.3%) lost a major molecular response after a median time off therapy of 5.3 months (range, 2-42 months). TFR rates at 12, 24, and 36 months were 48% (95% confidence interval [CI], 37.6%-61.5%), 42% (95% CI, 31.5%-55.4%), and 35% (95% CI, 24.4%-49.4%), respectively. No progression toward advanced-phase CML occurred, and no efficacy issue was observed upon TKI re-introduction. In univariate analysis, the speed of molecular relapse after the first TKI discontinuation attempt was the only factor significantly associated with outcome. The TFR rate at 24 months was 72% (95% CI, 48.8%-100%) in patients who remained in DMR within the first 3 months after the first TKI discontinuation and 36% (95% CI, 25.8%-51.3%) for others. CONCLUSIONS: This study is the first to demonstrate that a second TKI discontinuation attempt is safe and that a first failed attempt at discontinuing TKI does not preclude a second successful attempt. Cancer 2017;123:4403-10.
INTRODUCTION
Adenosine triphosphate-competitive tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia (CML) represent a major therapeutic breakthrough, and optimal responders have a near-normal life expectancy. 1 Although the recommendation is to continue lifelong treatment in clinical practice, a pilot study performed more than 10 years ago in patients with so-called "molecularly undetectable disease" for prolonged periods challenged the notion that TKIs may never be stopped. 2 TKI discontinuation was then evaluated prospectively, and it was demonstrated that imatinib, 2-9 nilotinib, or dasatinib 10, 11 could be safely stopped in patients who had long-lasting and deep molecular responses (DMRs). In parallel, important efforts were made to better standardize and score DMRs at different levels of quantitative reverse transcriptase-polymerase chain reaction (RT-qPCR) sensitivity; namely, molecular responses of MR4, MR4.5, and MR5.
Initial attempts of TKI cessation involved imatinib given either upfront or after failure on or intolerance to interferon-a (IFNa), followed by evaluations of discontinuation of the second-generation TKIs dasatinib and nilotinib given as first or subsequent lines of therapy. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] The pioneer Stopping Imatinib (STIM) and Trial of Withdrawing Imatinib in Stable Remission (TWISTER) imatinib-discontinuation trials were based on 2 major eligibility criteria: 1) 3 years of exposure to imatinib, and 2) 2 years of sustained MR4.5 with undetectable peripheral blood breakpoint cluster region-Abelson 1 (BCR-ABL1) transcripts (herein referred to as uMR4.5). 3, 5 Then, the observational A-STIM trial (A Study for Tyrosine Kinase Inhibitors Discontinuation) demonstrated the feasibility of imatinib discontinuation in patients with CML who maintained MR4.5 for 2 years regardless of whether they had detectable BCR-ABL1 transcripts. 6 Recently, the ongoing European Stop Tyrosine Kinase Inhibitor (EURO-SKI) trial explored less deep MR levels as thresholds for discontinuing imatinib, dasatinib, or nilotinib, enrolling patients who maintained MR4 for at least 1 year only. 13 In the STIM and TWISTER trials, the definitions for molecular relapse after TKI discontinuation were quite stringent. 5, 13 In the STIM study, a 1-log increase in BCR-ABL1 transcripts between 2 consecutive assessments defined a molecular relapse and triggered imatinib resumption. 13 In the TWISTER study, detectable BCR-ABL1 transcripts at any level in 2 consecutive assessments were considered as a molecular relapse and a trigger for restarting imatinib. 4, [7] [8] [9] [10] [11] 13 Then, the loss of a major molecular response (MMR) was proposed as a more reliable and safe molecular definition for relapse and treatment-free remission (TFR) was preferred over molecular relapse-free survival as the primary endpoint in most TKI-cessation studies.
Currently, TFR rates in TKI discontinuation studies are approximately 50%, although variations may be observed, depending on the definition of molecular relapse and characteristics of the study populations. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] 14 The most common factor associated with a successful outcome across studies is a long duration of TKI treatment before cessation. 3, 5 It has also been reported that the Sokal risk score and DMR duration are factors in success, and the role of different DMR levels also is under investigation in EURO-SKI. 13 In case of a molecular relapse, patients must rapidly resume TKI therapy, and no major efficacy issues have been reported. Currently, whether such relapsing patients may hope for re-attempting TFR is uncertain. In recent years, we observed that imatinib discontinuation after a first unsuccessful cessation attempt in a small series of 16 patients was feasible and did not automatically lead to a molecular relapse. 15 Thus we initiated a larger observational multicenter study named RE-STIM, to evaluate TFR after a second TKI discontinuation attempt.
MATERIALS AND METHODS

Patients
Patients aged 18 years who met criteria for chronicphase CML at diagnosis, as defined by the European LeukemiaNet, 16 were eligible for enrolment in RE-STIM, provided that they failed a first TKI discontinuation attempt, regained uMR4.5 after TKI resumption, and discontinued TKI again, regardless of the type of TKI in use before the first and second treatment-free phases and regardless of the reason for a second TKI discontinuation attempt (tolerability issues, proposal by treating physician, or patient willingness). Patients who previously were included in clinical trials like STIM, A-STIM, or EURO-SKI were eligible for enrollment; therefore, failure of a first TKI discontinuation attempt consisted in the loss of uMR4.5 with a 1-log increase in BCR-ABL1 transcripts between 2 consecutive assessments or loss of an MMR leading to treatment resumption. Patients who had undergone autologous or allogeneic hematopoietic stem cell transplantation, those with nonmajor BCR-ABL1 transcripts, and those with a history of progression to accelerated-phase or blast-crisis CML were excluded. RE-STIM was approved by the French Advisory Committee on Information Processing in Material Research in the Field of Health (CCTIRS) (no. 16 .849) and French data protection authority (CNIL). Informed consent was obtained from all patients in accordance with the Declaration of Helsinki.
Definition of Molecular Responses and Molecular Relapse
Molecular response assessments for BCR-ABL1 messenger RNA quantification by RT-qPCR and scoring of DMR followed European LeukemiaNet recommendations. 12, 17, 18 In brief, MR4.5 was defined as detectable BCR-ABL/ABL1 (internationally standardize [IS] ratio 0.0032%) or undetectable BCR-ABL1 in samples with 40,000 ABL1 transcripts until the end of 2012 and 32,000 ABL1 transcripts thereafter. MR4 was defined as detectable BCR-ABL/ABL1 (IS ratio 0.01%) or undetectable BCR-ABL1 in samples with 10,000 ABL1 transcripts. During the second attempt to discontinue TKI, a molecular relapse was defined as loss of MMR (BCR-ABL/ ABL1 IS ratio 0.1%) on any single test. BCR-ABL1
Original Article transcripts were monitored in the peripheral blood by RT-qPCR at the same frequency used in the STIM study, ie, monthly during the first 12 months, every 2 to 3 months during the second year, and every 3 to 6 months for up to 5 years. Monitoring of molecular response was performed in laboratories belonging to the French network of quality assurance and accreditation of molecular biology laboratories for hematologic malignancies (the French Molecular Biology Group in Hematology) (GBMHM). 19 After each TKI discontinuation attempt, the time of reappearance of BCR-ABL1 transcripts was defined as the first assessment indicating detectable BCR-ABL1 transcripts.
Endpoints and Statistical Methods
The primary endpoint was TFR, as estimated by KaplanMeier method and defined as the time elapsed between TKI discontinuation and the date of restarting TKI or MMR loss, whichever came first. For all other patients, data were censored at the date of last molecular evaluation. Log-rank tests were performed if necessary for the graphic illustrations of survival analyses. Secondary endpoints included safety (lack of progression to advancedphase CML and efficacy of treatment resumption). We also searched for factors associated with TFR after the second TKI discontinuation attempt. Descriptive analyses comparing cohorts were performed using common statistical tests, such as the t test or the Mann-Whitney U test for quantitative continuous variables and the chi-square test or the Monte-Carlo test for qualitative variables. We also searched for factors associated with TFR after the second TKI discontinuation attempt through simple regressions using a Cox model. The level of significance was set at 5%, and estimated hazard ratios were described with 95% confidence intervals (CIs). All statistical analyses were performed using R software (version 3.2.3; R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
Patient Characteristics
Seventy patients were included in the RE-STIM study as of October 1, 2016 . At the time of CML diagnosis, the median patient age was 51 years (range, 25-83 years) and the Sokal risk score was low, intermediate, high, and unknown in 35 patients (50%), 25 patients (36%), 9 patients (13%), and 1 patient (1%), respectively. Imatinib was received as the first-line TKI in all patients, either alone or combined with IFN (n 5 5) or cytarabine (n 5 9) within the French SPIRIT (STI571 Prospective Randomized Trial) clinical trial. 20 Nineteen patients received IFN before imatinib initiation. At the first TKI discontinuation attempt, the median duration of TKI treatment was 59 months (range, 30-146 months), and the median duration of uMR4.5 was 32 months (range, 17-78 months). TKI type at the first discontinuation attempt consisted of imatinib in 60 patients and secondline or subsequent line nilotinib or dasatinib in 10 patients (Fig. 1) . The reason for switching to nilotinib or dasatinib was imatinib intolerance in 8 patients and lack of an MMR in 2 patients. In agreement with RE-STIM inclusion criteria, all patients experienced a molecular relapse. The median time to uMR4.5 loss was 3 months (range, 1-22 months), and the median time to TKI resumption was 5 months (range, 1-36 months). The same TKI that was received before treatment cessation was restarted in 61 patients (Fig. 1) . Eight patients received dasatinib (n 5 3) or nilotinib (n 5 5) instead of imatinib, and 1 patient was switched back from dasatinib to imatinib (Fig. 1) . The median time to regain uMR4.5 after TKI resumption was 4.5 months (range, 1-26 months).
At the second TKI discontinuation attempt, the median patient age was 60 years (range, 36-93 years). The median time from TKI resumption to the second TKI discontinuation attempt was 32 months (range, 6-72 months), and the median duration of second uMR4.5 before second TKI discontinuation attempt was 25 months (range, 4-68 months) ( Table 1) . TKI type at the second discontinuation attempt consisted of imatinib in 50 patients, dasatinib in 7 patients, and nilotinib in 13 patients (Fig. 1) . The median follow-up after the second TKI discontinuation attempt was 38.3 months (range, 4.7-116 months).
Molecular Relapses and TFR After the Second TKI Discontinuation Attempt
At the time of this analysis, 45 patients (64%) lost an MMR after a median time off therapy of 5.3 months (range, 2-42 months). Most molecular relapses (54%) occurred during the first year after TKI discontinuation, with TFR probabilities at 6 and 12 months of 66% (95% CI, 55.5%-77.9%) and 48% (95% CI, 37.6%-61.5%), respectively (Fig. 2) . However, later onset molecular relapses occurred, as indicated by the steady decrease beyond 12 months: 42% (95% CI, 31.6%-55.4%) at 24 months and 35% (95% CI, 24.4%-49.4%) at 36 months (Fig. 2) . All relapsing patients restarted TKI treatment after a median of 5.3 months (range, 2-42 months). It is noteworthy that no progression toward advanced-phase CML was observed. The same TKI that was received before the second cessation was restarted in 27 (60%) relapsing patients. Dasatinib (n 5 5) or nilotinib (n 5 4) rather than imatinib was chosen in 9 patients because of prior tolerance issues, and 8 patients switched from a second-generation TKI to another (n 5 5) or to imatinib (n 5 3). The median follow-up of patients who resumed therapy was 39 months (range, 5-90 months). At the last follow-up, 34 patients regained uMR4.5 within a median timeframe of 6.5 months (range, 2-30 months), and 8 had an MMR Figure 2 . Treatment-free remission (TFR) is illustrated after a second attempt to discontinue tyrosine kinase inhibitor (TKI) treatment. The solid curve represents the TFR probability after the second attempt at TKI discontinuation, and the dashed curves define the confidence interval. The TFR probability at 6, 12, 24, and 36 months after the second attempt to discontinue TKI was 66%, 48%, 42%, and 35%, respectively.
response within a median of 4.6 months (range, 2-71 months). Two patients have not yet regained an MMR (with IS ratios of 0.16% and 0.24%), but follow-up is still short (<3 months). We note that 1 patient who lost an MMR at 6 months declined a TKI re-challenge. Consequently, BCR-ABL1 transcripts increased, and a complete hematologic response was lost at 24 months. Since the last blood test, the patient has been lost to follow-up. The median follow-up of the 25 patients (36%) who did not lose an MMR and remained treatment-free was 33.7 months (range, 6-116 months). Thirteen of these patients maintained uMR4.5 during the entire follow-up, whereas 12 had intermittently detectable BCR-ABL1 transcripts, but levels were always below the MMR threshold (results not shown). One patient died at age 93 years from a CML-unrelated cause (myocardial infarction 8 months after a second attempt to discontinue imatinib).
Factors Associated With Molecular Relapse
We tried to determine whether clinical or biologic variables were associated with outcome after a second TKI discontinuation attempt. In univariate analysis, we failed to identify any association between TFR and the following factors: age, sex, Sokal risk score, prior exposure to IFN, TKI in combination versus monotherapy, TKI type, TKI treatment duration, uMR4.5 duration before the first and second discontinuation attempts, and type of molecular relapse after the first discontinuation attempt (uMR4.5 vs MMR loss) ( Table 2) .
However, patients who lost uMR4.5 later than the median time to uMR4.5 loss after the first TKI discontinuation attempt (>3 months) had significantly less molecular relapses after the second TKI discontinuation attempt than those who lost uMR4.5 in less than 3 months (P 5 .024) ( Table 2 ). Therefore, we analyzed TFR after the second TKI discontinuation attempt according to BCR-ABL1 transcript levels soon after the first TKI discontinuation attempt and observed that TFR probabilities were significantly higher in patients who were still in MMR at 3 months than in those who had already lost MMR (P 5 .002) (Fig. 3) . Indeed, TFR probabilities at 36 months were 46% (95% CI, 30.6%-68.8%) Abbreviations: 2G, second-generation; CI, confidence interval; HR, hazard ratio; IFN, interferon; MMR, major molecular response; TKI, tyrosine kinase inhibitor; uMR4.5, undetectable molecular disease.
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Cancer November 15, 2017 in the group that maintained persistent uMR4.5, 31% (95% CI, 17.9%-54.8%) in the group that lost uMR4.5 but conserved MMR, and 0% (95% CI, 100%-100%) in the group that lost MMR (Fig. 3) . Consequently, TFR probabilities were significantly higher for patients who were still in uMR4.5 at 3 months than in those who had already lost uMR4.5 (P 5 .021) (Fig. 4) . Indeed, TFR probabilities at 36 months were 72% (95% CI, 48.8%-100%) in the persistent uMR4.5 group and 27% (95% CI, 16.8%-44%) in the group that lost uMR4.5.
DISCUSSION
Currently, patients with CML who achieve stable DMR on long-lasting TKI therapy have the opportunity to attempt treatment discontinuation, but only one-half of them successfully discontinue TKI therapy. 21 Relapsing patients must resume therapy; and, although they regain DMR upon TKI re-challenge, whether a second treatment discontinuation attempt is feasible is unknown. For the first time, we demonstrate that a second TKI cessation attempt is safe and potentially successful. Figure 3 . The probability of achieving treatment-free remission (TFR) is illustrated according to molecular status at 3 months after the first attempt to discontinue tyrosine kinase inhibitor (TKI) therapy. The blue curve represents patients who remained in persistent, undetectable molecular disease (uMR4.5) (undetectable BCR-ABL1 in samples with 40,000 ABL1 transcripts until the end of 2012 and 32,000 ABL1 transcripts later on; see definition page 2 in "definition of molecular responses and molecular relapse") at 3 months (M3); the green curve represents those who lost uMR4.5 but retained a major molecular response (MMR); and the red curve represents patients who lost an MMR within 3 months. TFR probabilities at 36 months were 46% (95% confidence interval [CI], 30.6%-68.8%) in the uMR4.5 group, 31% (95% CI, 17.9%-54.8%) in the MR4.5 group with conserved MMR, and only 0% (95% CI, 100%-100%) in the group that lost an MMR. Figure 4 . The probability of achieving treatment-free remission (TFR) is illustrated according to undetectable/detectable status at 3 months after the first attempt to discontinue tyrosine kinase inhibitor (TKI) therapy. The blue curve represents patients who remained in persistent, undetectable molecular disease (uMR4.5) (undetectable BCR-ABL1 in samples with 40,000 ABL1 transcripts until the end of 2012 and 32,000 ABL1 transcripts later on; see definition page 2 in "definition of molecular responses and molecular relapse") at 3 months (M3), and the red curve represents patients who lost uMR4.5 within 3 months. TFR probabilities at 36 months were 72% (95% confidence interval [CI], 48.8%-100%) in the persistent uMR4.5 group and 27% (95% CI, 16.8%-44%) in the group that lost uMR4.5.
On the basis of the "loss of MMR" criterion as a trigger for treatment resumption, we report TFR rates of 42% at 24 months and 35% at 36 months. Currently, the only point of comparison is the first attempt TFR studies, such as STIM, A-STIM, the Imatinib Suspension and Validation (ISAV) Study, the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON), the Japan survey, and TWISTER. [3] [4] [5] [6] [7] [8] Studies in which TKIs were discontinued under comparable circumstances (minimal treatment length and DMR level and with the same molecular relapse definition) reported estimated TFR rates at 24 months from 52% to 64%. Thus, a second attempt of TKI discontinuation appears to be less successful than a first attempt. We failed to identify the usual predictive factors associated with molecular relapse during a first attempt, such as the Sokal risk score and uMR4.5 and TKI duration (Table 2) . This difference could have been explained by the first uMR4.5 duration, which was 2 years in TFR studies and a minimum of 1 year in the current RE-STIM study; however, molecular stringency (uMR4.5 2 years) and second TKI duration 3 years do not appear to be the main factors for a successful or unsuccessful second attempt of TKI discontinuation (data not shown). It is noteworthy, in the patients who maintained a persistent uMR4.5 at 3 months, TFR rates were similar to those from the first attempt cessation studies. Indeed, patients who remain in uMR4.5 at 3 months during the first discontinuation have a better TFR at the second discontinuation, with a somewhat identical TFR probability at 24 and 36 months (72%; 95% CI, 48.8%-100%) compared with 36% (95% CI, 25.8%-51.3%) and 27% (95% CI, 16.8%-44%) in the other patients.
Another difference observed in our study compared with the majority of TFR studies is the molecular relapse pattern. Mathematical models of CML indicate that the average rate of exponential increase after stopping imatinib is 0.09 6 0.05 per day, corresponding to a doubling time of 8 days. 22 This explains why, in most of the TKI cessation studies, the majority of molecular relapses occurred during the first 6 months after discontinuation, with only a few relapses observed at later time points. 3, 5, 6, 11 Differing from molecular relapse profiles after the first attempt, here, we have demonstrated more delayed relapses spread over time, leading to a lower TFR rate of 35% (95% CI, 24.4%-49.4%) at 36 months and encouraging us to propose close molecular monitoring even after 24 months.
Molecular relapses are related to the reactivation of clones entering the cell cycle 23, 24 and may be related to various factors, including residual leukemic stem cell burden, but the lack of stringent criteria impacting on the success of second TKI discontinuation does not support this hypothesis. The delayed relapse pattern observed in the RE-STIM study might be better explained by an indirect mechanism as the late failure or exhaustion of the autologous immune system 25 or as long-term microenvironment alterations. [26] [27] [28] Patients who remain in uMR4.5 at 3 months during the first discontinuation have a higher rate of TFR at the second discontinuation compared with the other patients. Therefore, the impact of delaying a molecular relapse after discontinuation on the success of this strategy could support the idea of controlling the reactivation of residual leukemic stem cells.
In conclusion, a second attempt to discontinue TKI therapy in patients who failed a first discontinuation and subsequently regained uMR4.5 after TKI re-challenge is safe. This strategy is more successful in patients who relapse later than 3 months during a first discontinuation attempt. Very close and prolonged molecular monitoring is required. To confirm the long-term safety of this strategy, patients should be registered or included in a prospective trial.
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